---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-079104"
form_type: "8-K"
ticker: "ORIC"
cik: "0001796280"
company_name: "Oric Pharmaceuticals, Inc."
filed_at: "2023-03-24T23:59:59+00:00"
generated_at: "2026-06-17T16:57:29.581014+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# ORIC Pharmaceuticals amends bylaws to update proxy rules and conform to Delaware law

## Summary
- Enhanced disclosure requirements for stockholder nominations and proposals.
- Adopted procedural changes to align with SEC universal proxy rules.
- Revised meeting provisions per recent DGCL amendments (notice, quorum, adjournment).
- Updated exclusive forum provisions and officer/committee authority.
- Made ministerial clarifications and conforming revisions throughout.

## SEC filing metadata
- accession: 0001193125-23-079104
- form_type: 8-K
- ticker: ORIC
- cik: 0001796280
- company_name: Oric Pharmaceuticals, Inc.
- filed_at: 2023-03-24T23:59:59+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.03, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1796280/000119312523079104/0001193125-23-079104-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1796280/000119312523079104/d487262d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-079104
- JSON: https://secwatch.observer/filing/0001193125-23-079104.json
- Plain text: https://secwatch.observer/filing/0001193125-23-079104.txt

## Key facts
- Governance Changes
  Oric Pharmaceuticals, Inc.: The Board approved Amended and Restated Bylaws to enhance procedural mechanics and disclosure requirements for stockholder nominations, update provisions for universal proxy rules, conform to DGCL amendments, revise director/committee/officer provisions, clarify exclusive forum, and make conforming (effective 2023-03-20).
  - Change: bylaw amendment
  - Effective: 2023-03-20
  source text: On March 20, 2023, the Board of Directors (the “Board”) of ORIC Pharmaceuticals, Inc. (the “Company”) approved the Company’s Amended and Restated Bylaws (the “Amended and Restated Bylaws”). The Amended and Restated Bylaws were amended and restated to, among other things: • enhance procedural mechanics and disclosure requirements in connection with stockholder nominations of directors and submissions of proposals regarding other business at the Company’s annual meeting of stockholders (except for proposals properly made in accordance with Rule 14a-8 under the Securities Exchange Act of 1934), including by requiring additional background information and disclosures regarding proposing stockholders, proposed nominees and business, and other persons related to a stockholder’s solicitation of proxies; • change certain provisions relating to stockholder nominees for election as a director to address the universal proxy rules adopted by the Securities and Exchange Commission; • revise certain
  evidence_url: https://www.sec.gov/Archives/edgar/data/1796280/000119312523079104/0001193125-23-079104-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.